Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385212779> ?p ?o ?g. }
- W4385212779 endingPage "3706" @default.
- W4385212779 startingPage "3706" @default.
- W4385212779 abstract "In polycythemia vera (PV), the prognostic relevance of an ELN-defined complete response (CR) to hydroxyurea (HU), the predictors of response, and patients' triggers for switching to ruxolitinib are uncertain. In a real-world analysis, we evaluated the predictors of response, their impact on the clinical outcomes of CR to HU, and the correlations between partial or no response (PR/NR) and a patient switching to ruxolitinib. Among 563 PV patients receiving HU for ≥12 months, 166 (29.5%) achieved CR, 264 achieved PR, and 133 achieved NR. In a multivariate analysis, the absence of splenomegaly (p = 0.03), pruritus (p = 0.002), and a median HU dose of ≥1 g/day (p < 0.001) remained associated with CR. Adverse events were more frequent with a median HU dose of ≥1 g/day. Overall, 283 PR/NR patients (71.3%) continued HU, and 114 switched to ruxolitinib. In the 449 patients receiving only HU, rates of thrombosis, hemorrhages, progression, and overall survival were comparable among the CR, PR, and NR groups. Many PV patients received underdosed HU, leading to lower CR and toxicity rates. In addition, many patients continued HU despite a PR/NR; however, splenomegaly and other symptoms were the main drivers of an early switch. Better HU management, standardization of the criteria for and timing of responses to HU, and adequate intervention in poor responders should be advised." @default.
- W4385212779 created "2023-07-25" @default.
- W4385212779 creator A5002133396 @default.
- W4385212779 creator A5006023644 @default.
- W4385212779 creator A5007773747 @default.
- W4385212779 creator A5008040655 @default.
- W4385212779 creator A5008566093 @default.
- W4385212779 creator A5009267255 @default.
- W4385212779 creator A5014501048 @default.
- W4385212779 creator A5020333760 @default.
- W4385212779 creator A5026258863 @default.
- W4385212779 creator A5026430732 @default.
- W4385212779 creator A5026992937 @default.
- W4385212779 creator A5029759839 @default.
- W4385212779 creator A5033633636 @default.
- W4385212779 creator A5037355780 @default.
- W4385212779 creator A5037607824 @default.
- W4385212779 creator A5045651843 @default.
- W4385212779 creator A5046369034 @default.
- W4385212779 creator A5052893667 @default.
- W4385212779 creator A5054304877 @default.
- W4385212779 creator A5057084037 @default.
- W4385212779 creator A5060107199 @default.
- W4385212779 creator A5062047451 @default.
- W4385212779 creator A5064943800 @default.
- W4385212779 creator A5066631109 @default.
- W4385212779 creator A5068514968 @default.
- W4385212779 creator A5070044155 @default.
- W4385212779 creator A5071926851 @default.
- W4385212779 creator A5074396899 @default.
- W4385212779 creator A5078900656 @default.
- W4385212779 creator A5080563685 @default.
- W4385212779 creator A5084359235 @default.
- W4385212779 creator A5085036155 @default.
- W4385212779 creator A5086760651 @default.
- W4385212779 creator A5087722204 @default.
- W4385212779 creator A5089760320 @default.
- W4385212779 creator A5090469515 @default.
- W4385212779 creator A5091328004 @default.
- W4385212779 date "2023-07-21" @default.
- W4385212779 modified "2023-10-03" @default.
- W4385212779 title "Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study" @default.
- W4385212779 cites W1968468753 @default.
- W4385212779 cites W1980972742 @default.
- W4385212779 cites W1983958439 @default.
- W4385212779 cites W2000445173 @default.
- W4385212779 cites W2053961852 @default.
- W4385212779 cites W2068493370 @default.
- W4385212779 cites W2070929302 @default.
- W4385212779 cites W2122395736 @default.
- W4385212779 cites W2149373649 @default.
- W4385212779 cites W2158669800 @default.
- W4385212779 cites W2178961707 @default.
- W4385212779 cites W2199810342 @default.
- W4385212779 cites W2207219039 @default.
- W4385212779 cites W2217750424 @default.
- W4385212779 cites W2339658711 @default.
- W4385212779 cites W2495529699 @default.
- W4385212779 cites W2550454005 @default.
- W4385212779 cites W2559562829 @default.
- W4385212779 cites W2803381821 @default.
- W4385212779 cites W3001373379 @default.
- W4385212779 cites W3008905509 @default.
- W4385212779 cites W3198080127 @default.
- W4385212779 cites W4225576462 @default.
- W4385212779 cites W4280594357 @default.
- W4385212779 cites W4280625521 @default.
- W4385212779 cites W4367596117 @default.
- W4385212779 doi "https://doi.org/10.3390/cancers15143706" @default.
- W4385212779 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37509367" @default.
- W4385212779 hasPublicationYear "2023" @default.
- W4385212779 type Work @default.
- W4385212779 citedByCount "0" @default.
- W4385212779 crossrefType "journal-article" @default.
- W4385212779 hasAuthorship W4385212779A5002133396 @default.
- W4385212779 hasAuthorship W4385212779A5006023644 @default.
- W4385212779 hasAuthorship W4385212779A5007773747 @default.
- W4385212779 hasAuthorship W4385212779A5008040655 @default.
- W4385212779 hasAuthorship W4385212779A5008566093 @default.
- W4385212779 hasAuthorship W4385212779A5009267255 @default.
- W4385212779 hasAuthorship W4385212779A5014501048 @default.
- W4385212779 hasAuthorship W4385212779A5020333760 @default.
- W4385212779 hasAuthorship W4385212779A5026258863 @default.
- W4385212779 hasAuthorship W4385212779A5026430732 @default.
- W4385212779 hasAuthorship W4385212779A5026992937 @default.
- W4385212779 hasAuthorship W4385212779A5029759839 @default.
- W4385212779 hasAuthorship W4385212779A5033633636 @default.
- W4385212779 hasAuthorship W4385212779A5037355780 @default.
- W4385212779 hasAuthorship W4385212779A5037607824 @default.
- W4385212779 hasAuthorship W4385212779A5045651843 @default.
- W4385212779 hasAuthorship W4385212779A5046369034 @default.
- W4385212779 hasAuthorship W4385212779A5052893667 @default.
- W4385212779 hasAuthorship W4385212779A5054304877 @default.
- W4385212779 hasAuthorship W4385212779A5057084037 @default.
- W4385212779 hasAuthorship W4385212779A5060107199 @default.
- W4385212779 hasAuthorship W4385212779A5062047451 @default.
- W4385212779 hasAuthorship W4385212779A5064943800 @default.
- W4385212779 hasAuthorship W4385212779A5066631109 @default.